- Report
- February 2024
- 96 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- August 2024
- 200 Pages
China
From €3737EUR$4,000USD£3,161GBP
- Report
- August 2024
- 100 Pages
China
From €1682EUR$1,800USD£1,423GBP
Benproperine is a respiratory drug used to treat bronchial asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. It is a long-acting beta-agonist (LABA) that works by relaxing the muscles of the airways, allowing more air to flow in and out of the lungs. Benproperine is available in both oral and inhaled forms, and is often used in combination with other medications to provide better symptom control.
Benproperine is a widely used drug in the respiratory market, and is often prescribed as a first-line treatment for asthma and COPD. It is also used to treat other respiratory conditions such as bronchitis and emphysema. Benproperine is generally well-tolerated and has few side effects, making it a popular choice for many patients.
The benproperine market is highly competitive, with many companies offering their own versions of the drug. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Merck, Novartis, and Boehringer Ingelheim. Show Less Read more